{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:42:52Z","timestamp":1792806172893,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fundaci\u00f3 Instituci\u00f3 dels Centres de Recerca de Catalunya","id":[{"id":"https:\/\/ror.org\/01bkbaq61","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>In patients with endometrial cancer (EC) with metastases at diagnosis, palliative treatment is the only therapy considered and to our knowledge there is no literature on the evolution of these patients following external-beam-irradiation (EBRT) and image-guided brachytherapy (IGBT). We present the clinical outcomes of 11 FIGO 2009 stage-IVB EC patients treated with IGBT\u2009\u00b1\u2009EBRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/patients<\/jats:title>\n                    <jats:p>From July 2009 to February 2018, 11 stage IVB patients were treated with IGBT\u2009\u00b1\u2009EBRT in 4 European centres. The treatments and the outcomes of these patients were analysed. Statistics: Kaplan-Meier and descriptive analysis were used for analysing overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age was 63\u00a0years (46\u201379) and the median follow-up was 39\u00a0months (8\u2013128). The sites of metastases were reported in 8\/11 patients: the lung in 4 patients, peritoneal and liver metastasis in one, pleural metastasis in one, bone in one and inguinal lymph nodes in one. Seven patients underwent chemotherapy (5 achieving complete response (CR)). Two patients received IGBT alone and 9 EBRT\u2009+\u2009IGBT. Three developed uterine relapse, 3 lymph node relapse and all died. Four had distant metastases and only one was alive after treatment. The OS was 69.3% at 2 and 3\u00a0years and 41.6% at 5 and 10\u00a0years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this series, patients with stage IVB EC with CR after chemotherapy and treated with IGBT\u2009\u00b1\u2009EBRT achieved an OS of 41.6% at 5 and 10\u00a0years. Local treatment with EBRT\u2009\u00b1\u2009IGBT should be considered mainly in good responders to chemotherapy and should be validated in prospective trials including biological markers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-026-04391-9","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T11:33:20Z","timestamp":1780832000000},"page":"5247-5254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Image-guided brachytherapy in patients with inoperable FIGO 2009 stage IVB endometrial cancer who were not candidates for palliative surgery"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7832-334X","authenticated-orcid":false,"given":"Angeles","family":"Rovirosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowen","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Limkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Wojcieszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Stankiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Segedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Van Limbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,7]]},"reference":[{"issue":"6","key":"4391_CR1","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/cancers17061035","volume":"17","author":"F Guo","year":"2025","unstructured":"Guo F, Adekanmbi V, Hsu CD, Hoang TN, Baillargeon JC, Bereson AB. Trends in uterine cancer incidence among premenopausal and postmenopausal women in the United States 2001-2020. Cancer. 2025;17(6):1035.","journal-title":"Cancer"},{"key":"4391_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-023-07368-z","author":"DJ Krankenberg","year":"2024","unstructured":"Krankenberg DJ, Muallem MZ, Pietzner K, Chekerov R, Armbrust R, Beteta C, et al. Ovarian cancer management in an ESGO ovarian cancer center of excellence: a systematic case study of the interprofessional and interdisciplinary interaction. Arch Gynecol Obstet. 2024. https:\/\/doi.org\/10.1007\/s00404-023-07368-z.","journal-title":"Arch Gynecol Obstet"},{"key":"4391_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/ijgo.14923","volume":"162","author":"JS Berek","year":"2023","unstructured":"Berek JS, Matias-Guiu J, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet. 2023;162:383\u201394.","journal-title":"Int J Gynaecol Obstet"},{"issue":"4","key":"4391_CR4","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3390\/cancers14040906","volume":"14","author":"M Glatzer","year":"2022","unstructured":"Glatzer M, Tanderup K, Rovirosa A, Fokdal L, Ordeanu C, Tagliaferri L, et al. Role of brachytherapy in the postoperative management of endometrial cancer: decision-making analysis among experienced European radiation oncologists. Cancers (Basel). 2022;14(4):906.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"4391_CR5","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","volume":"26","author":"N Concin","year":"2025","unstructured":"Concin N, Matias-Guiu X, Cibula D, Colombo N, Creutzberg CL, et al. ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncol. 2025;26(8):e423\u201335.","journal-title":"Lancet Oncol"},{"key":"4391_CR6","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.3390\/cancers15215123","volume":"15","author":"VA Capozi","year":"2023","unstructured":"Capozi VA, Scarpelli E, De Finis A, Rotondellla I, Scebba D, Gallinelli A, et al. Optimal management for stage IVB endometrial cancer: a systematic review. Cancers. 2023;15:5123.","journal-title":"Cancers"},{"key":"4391_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijgo.2009.02.010","volume":"105","author":"W Creasman","year":"2009","unstructured":"Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009;105:109.","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"4391_CR8","first-page":"529","volume":"36","author":"O Kraemer","year":"2015","unstructured":"Kraemer O, Rapiti E, Huber D, Lopes-Raimundo E, Usel M, Bouchardy C, et al. Stage IVB endometrial cancer: clinical course and survival of patients with single and multiple metastases. Eur J Gynaecol Oncol. 2015;36(5):529\u201332.","journal-title":"Eur J Gynaecol Oncol"},{"issue":"23","key":"4391_CR9","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","volume":"388","author":"RN Eskander","year":"2023","unstructured":"Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388(23):2159\u201370.","journal-title":"N Engl J Med"},{"issue":"2","key":"4391_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s12094-021-02680-z","volume":"24","author":"A Rovirosa","year":"2022","unstructured":"Rovirosa A, Zhang Y, Chargari C, Cooper R, Bownes P, Wojcieszek P, et al. Exclusive 3D-brachytherapy as a good option for stage-I inoperable group; GEC-ESTRO endometrial cancer: a retrospective analysis in the gynaecological cancer GEC-ESTRO working group. Clin Transl Oncol. 2022;24(2):254\u201365.","journal-title":"Clin Transl Oncol"},{"issue":"19","key":"4391_CR11","doi-asserted-by":"publisher","first-page":"4750","DOI":"10.3390\/cancers15194750","volume":"15","author":"\u00c1 Rovirosa","year":"2023","unstructured":"Rovirosa \u00c1, Zhang Y, Tanderup K, Ascaso C, Chargari C, Van der Steen-Banasik E, et al. Stages I-III inoperable endometrial Carcinoma: a retrospective analysis by the gynaecological cancer GEC-ESTRO working group of patients treated with external beam irradiation and 3D-image guided Brachytherapy. Cancers (Basel). 2023;15(19):4750.","journal-title":"Cancers (Basel)"},{"key":"4391_CR12","doi-asserted-by":"crossref","unstructured":"Koskas M., Amant F., Mirza M.R., Creutzberg C.L. Creutzberg. Cancer of the corpus uteri: 2021 update. Int. J. Gynaecol. Obstet. 2021; 155 Suppl 1:45\u201360.","DOI":"10.1002\/ijgo.13866"},{"key":"4391_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.brachy.2024.06.005","volume":"23","author":"A Luquez","year":"2024","unstructured":"Luquez A, Egleston BL, Pl L, Howell KJ, Price JC. National cancer database analysis of radiation therapy consolidation modality and dose for inoperable endometrial cancer. Brachyhterapy. 2024;23:623\u201333 (In press).","journal-title":"Brachyhterapy"},{"key":"4391_CR14","unstructured":"Common terminology criteria for adverse events (CTCAE) version 4.0. 2009. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf.Accessed 20 Oct 2020."},{"key":"4391_CR15","unstructured":"Maller R.A., Zhou X. Analysis with long-term survivors. In: Wiley, editor. Applied Probability and Statistics. Virginia University; Charlottesville, VA. de Wiley Series in Probability and Statistics. Vol 16."},{"key":"4391_CR16","volume-title":"Biostatistics: basic concepts and methodology for the health sciences","author":"WW Daniel","year":"2017","unstructured":"Daniel WW, Cross CL. Biostatistics: basic concepts and methodology for the health sciences. Hoboken, NJ: John Wiley and Sons (Wiley Series in Probability and Statistics); 2017."},{"issue":"5","key":"4391_CR17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.brachy.2015.06.002","volume":"14","author":"JK Schwarz","year":"2015","unstructured":"Schwarz JK, Beriwal S, Esthappan J, Erickson B, Feltmate C, et al. Consensus statement for brachytherapy for the treatment of medically inoperable endometrial cancer. Brachytherapy. 2015;14(5):587\u201399.","journal-title":"Brachytherapy"},{"key":"4391_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1 introduction\u2014GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383\u201394.","journal-title":"J Clin Epidemiol"},{"key":"4391_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1006\/gyno.2000.5843","volume":"78","author":"RE Bristow","year":"2000","unstructured":"Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz F. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gyn ecol Oncol. 2000;78:85\u201391.","journal-title":"Gyn ecol Oncol"},{"key":"4391_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ygyno.2023.05.069","volume":"175","author":"PJ Haight","year":"2023","unstructured":"Haight PJ, Riedinger CJ, Backes FJ, O\u2019Malley DM, Cosgrove CM. The right time for change: a report on the heterogeneity of IVB endometrial cancer and improved risk-stratification provided by new 2023 FIGO staging criteria. Gynecol Oncol. 2023;175:32\u201340.","journal-title":"Gynecol Oncol"},{"key":"4391_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ygyno.2013.10.035","volume":"132","author":"LJ Lee","year":"2014","unstructured":"Lee LJ, DeMaria R, Berkowitz R, Matulonis U, Viswanathan AN. Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen. Gynecol Oncol. 2014;132:65\u20139.","journal-title":"Gynecol Oncol"},{"key":"4391_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ygyno.2012.08.012","volume":"127","author":"T Eto","year":"2012","unstructured":"Eto T, Saito T, Kasamatsu T, Nakanishi T, Yokota H, Satoh T, et al. Clinicopathological prognostic factors and the role of cytoreduction in surgical stage IVB endometrial cancer: a retrospective multi-institutional analysis of 248 patients in Japan. Gynecol Oncol. 2012;127:338\u201344.","journal-title":"Gynecol Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04391-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04391-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04391-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:02:17Z","timestamp":1792803737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04391-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,7]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["4391"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04391-9","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,7]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This multicentre manuscript received ethical approval (HCB\/2018\/0341).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Obtained from each centre.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors agree to submit the manuscript to the journal.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}